Each year, more than 1.7 million new cases of cancer are diagnosed in the United States. Precision medicine has improved the outlook for some cancer patients by tailoring treatment strategies based on the unique genomic makeup of each tumor. However, a vast majority of patients do not benefit from precision medicine.
Most drugs are recommended based on specific DNA mutations - typically found only in a small fraction of patients. Moreover, cancers develop drug resistance, necessitating new treatment strategies that target the evolving tumor.
Our mission is to accelerate treatment success using novel prognostic and drug response models that overcome current barriers of precision oncology by encompassing tumors without actionable mutations.
Unravel Genomics resolves drug response states in patient tumors through the application of novel computational and mathematical models to state-of-the-art genomic measurements.
We have the ability to measure the state of cells within a tumor during the course of a patient’s therapy, identify cells that are responsive or resistant to the treatment and determine the mechanisms behind resistance.
This profound genomic innovation transforms our ability to both predict outcomes, and to understand and target patient-specific vulnerabilities. With the marriage of this deep data to cutting edge mathematical analysis, it is now possible to fit the unmet need of personalized medicine.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.